Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.50 |
| ▸ | TPH1 | P17752 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7229407 | 0.99 | ALDH1A1 (0.57) | ALDH1A1ROCK2ROCK1TPH1OPRK1 | |
| SCHEMBL7349516 | 0.90 | TPH1 (0.57) | ROCK2ROCK1TPH1LDHA | |
| SCHEMBL7349532 | 0.90 | TPH1 (0.57) | ROCK2ROCK1TPH1LDHA | |
| SCHEMBL20474581 | 0.85 | ROCK2 (0.52) | ROCK2ROCK1TPH1OPRK1AAK1 | |
| SCHEMBL18554064 | 0.85 | ROCK2 (0.52) | ROCK2ROCK1TPH1OPRK1AAK1 | |
| SCHEMBL6504755 | 0.85 | CSNK2A1 (0.51) | ALDH1A1ROCK2ROCK1 | |
| SCHEMBL7410313 | 0.84 | PPARG (0.55) | ALDH1A1TPH1ITGA4ITGB7 | |
| SCHEMBL5787820 | 0.84 | PPARG (0.55) | ALDH1A1TPH1ITGA4ITGB7 | |
| SCHEMBL5263532 | 0.84 | PPARG (0.55) | ALDH1A1TPH1ITGA4ITGB7 | |
| SCHEMBL3833206 | 0.84 | ALDH1A1 (0.51) | ALDH1A1ROCK2ROCK1TPH1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613782-B2 | For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders | NOVARTIS AG (CH) | 2003-09-02 | — | — | US | disclosed |
| US-6423727-B1 | Certain thiol inhibitors of endothelin-converting enzyme | NOVARTIS AG (CH) | 2002-07-23 | — | — | US | disclosed |
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | LOMBAERT STEPHANE DE (US) | 2002-06-27 | — | — | US | disclosed |
| EP-1073674-A1 | THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055726-A1 | CERTAIN THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | ALDH1A1 139/4885ROCK2 3617/4885ROCK1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.